Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NYSE:QGEN NASDAQ:ROIV NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.50-0.1%$49.40$21.72▼$54.60$9.85B1.252.38 million shs2.16 million shsQGENQIAGEN$45.60-0.3%$48.14$37.63▼$51.88$10.17B0.641.42 million shs903,166 shsROIVRoivant Sciences$14.74-1.3%$12.35$8.73▼$16.05$10.20B1.158.75 million shs8.04 million shsXENEXenon Pharmaceuticals$37.31-0.1%$35.57$26.74▼$46.00$2.88B1.17624,439 shs468,676 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.08%+0.02%+4.93%+16.04%+102.76%QGENQIAGEN-0.25%+0.01%-8.27%-3.95%+5.50%ROIVRoivant Sciences-1.34%+3.95%+23.66%+29.30%+23.87%XENEXenon Pharmaceuticals-0.25%+4.63%-3.94%+17.47%-5.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.50-0.1%$49.40$21.72▼$54.60$9.85B1.252.38 million shs2.16 million shsQGENQIAGEN$45.60-0.3%$48.14$37.63▼$51.88$10.17B0.641.42 million shs903,166 shsROIVRoivant Sciences$14.74-1.3%$12.35$8.73▼$16.05$10.20B1.158.75 million shs8.04 million shsXENEXenon Pharmaceuticals$37.31-0.1%$35.57$26.74▼$46.00$2.88B1.17624,439 shs468,676 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.08%+0.02%+4.93%+16.04%+102.76%QGENQIAGEN-0.25%+0.01%-8.27%-3.95%+5.50%ROIVRoivant Sciences-1.34%+3.95%+23.66%+29.30%+23.87%XENEXenon Pharmaceuticals-0.25%+4.63%-3.94%+17.47%-5.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9424.16% UpsideQGENQIAGEN 2.27Hold$49.698.95% UpsideROIVRoivant Sciences 3.00Buy$19.9435.26% UpsideXENEXenon Pharmaceuticals 3.00Buy$53.3042.86% UpsideCurrent Analyst Ratings BreakdownLatest XENE, QGEN, BBIO, and ROIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025ROIVRoivant SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.009/18/2025ROIVRoivant SciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.009/18/2025ROIVRoivant SciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $21.009/18/2025ROIVRoivant SciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$16.00 ➝ $20.009/18/2025ROIVRoivant SciencesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$12.00 ➝ $16.509/18/2025ROIVRoivant SciencesLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $22.009/18/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.009/15/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/3/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$55.00 ➝ $70.009/3/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$48.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M44.37N/AN/A($7.71) per share-6.68QGENQIAGEN$1.98B5.12$3.20 per share14.27$16.05 per share2.84ROIVRoivant Sciences$23.23M433.25N/AN/A$7.45 per share1.98XENEXenon Pharmaceuticals$9.43M305.09N/AN/A$9.90 per share3.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)QGENQIAGEN$83.59M$1.6926.9418.542.4118.30%14.77%8.87%11/5/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest XENE, QGEN, BBIO, and ROIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/A8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025QGENQIAGEN$0.60$0.60N/A$0.44$523.97 million$533.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AQGENQIAGEN$0.250.55%N/A14.79%N/AROIVRoivant SciencesN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08QGENQIAGEN0.251.611.35ROIVRoivant SciencesN/A40.5440.54XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%QGENQIAGEN70.00%ROIVRoivant Sciences64.76%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%QGENQIAGEN9.00%ROIVRoivant Sciences10.80%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableQGENQIAGEN5,765222.29 million202.29 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableXENE, QGEN, BBIO, and ROIV HeadlinesRecent News About These CompaniesAssenagon Asset Management S.A. Increases Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 23 at 3:40 AM | marketbeat.comVoya Investment Management LLC Has $1.61 Million Stake in Xenon Pharmaceuticals Inc. $XENESeptember 23 at 3:04 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by BrokeragesSeptember 23 at 2:06 AM | marketbeat.comHarbor Capital Advisors Inc. Sells 26,555 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 19, 2025 | marketbeat.comInvestors Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)September 18, 2025 | marketbeat.comWhy Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?September 10, 2025 | zacks.comAlliancebernstein L.P. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Decreases Stake in Xenon Pharmaceuticals Inc. $XENESeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Purchases 78,390 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 7, 2025 | marketbeat.comWells Fargo & Company Reiterates Overweight Rating for Xenon Pharmaceuticals (NASDAQ:XENE)September 5, 2025 | marketbeat.comAlly Bridge Group NY LLC Trims Position in Xenon Pharmaceuticals Inc. $XENESeptember 5, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Acquired by Adage Capital Partners GP L.L.C.September 5, 2025 | marketbeat.comInvestors Buy High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)September 5, 2025 | marketbeat.comXenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at Royal Bank Of CanadaSeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Has $4.28 Million Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comFirst Light Asset Management LLC Sells 532,676 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE is Vestal Point Capital LP's 9th Largest PositionSeptember 4, 2025 | marketbeat.comBirchview Capital LP Has $705,000 Stake in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Raises Stock Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 646,271 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comXenon Pharmaceuticals assumed with an Overweight at Wells FargoSeptember 3, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXENE, QGEN, BBIO, and ROIV Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$51.50 -0.04 (-0.08%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$51.25 -0.25 (-0.49%) As of 08:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.QIAGEN NYSE:QGEN$45.60 -0.13 (-0.28%) Closing price 09/23/2025 03:59 PM EasternExtended Trading$45.27 -0.33 (-0.73%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Roivant Sciences NASDAQ:ROIV$14.74 -0.20 (-1.34%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$14.71 -0.03 (-0.20%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Xenon Pharmaceuticals NASDAQ:XENE$37.31 -0.04 (-0.11%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$36.94 -0.38 (-1.01%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
